H
100.67
-1.01 (-0.99%)
| Previous Close | 101.68 |
| Volume | 1,430,725 |
| Price / Earnings (Forward) | 11.24 |
| Price / Sales | 6.90 |
| Price / Book | 103.55 |
| 52 Weeks Range |
| Profit Margin | 44.76% |
| Operating Margin (TTM) | 53.44% |
| Diluted EPS (TTM) | 3.76 |
| Quarterly Revenue Growth (YOY) | 35.20% |
| Quarterly Earnings Growth (YOY) | 53.70% |
| Total Debt/Equity (MRQ) | 318.67% |
| Current Ratio (MRQ) | 8.39 |
| Operating Cash Flow (TTM) | 503.86 M |
| Levered Free Cash Flow (TTM) | 402.43 M |
| Return on Assets (TTM) | 18.50% |
| Return on Equity (TTM) | 147.06% |
News Mood
Positive
- Will HALO's Partner Royalties Drive Growth for the Rest of 2026?
- Halozyme Therapeutics (HALO) Stock Looks In Line As ENHANZE Approval Lands
Negative
AIStockmoo Score
| Value 35% | -0.8 |
| AI Insight info | NA |
| Relative Valuation info | -2.7 |
| Financial Health info | 2.0 |
| Timing 35% | -1.3 |
| AI Technical info | NA |
| Technical Oscillators info | -0.5 |
| Technical Moving Averages info | -2.5 |
| Smart Money 30% | 0.5 |
| Analyst Consensus info | 0.0 |
| Insider Activity info | NA |
| News Mood info | 1.9 |
| Environment | ×1.21 |
| Macro Environment info | -3.3 |
| Sector vs Market (6M) | -24.2% |
| Pillar Agreement | ×1.07 |
| Not in score | |
| Price Volatility info | -0.4 |
| Final Score | -0.75 |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Halozyme Therapeutics, Inc. | Mixed | Bullish |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| HALO | - | - | - | 103.55 |
| IPA | 96 M | - | - | 5.98 |
| TNYA | - | - | - | 1.45 |
| CRVO | - | - | - | 1.54 |
| CELU | - | - | - | - |
| RVPH | - | - | - | 0.290 |
Select this tab to load the latest available analysis.
|
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 1.11% |
| % Held by Institutions | 101.53% |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 12 Nov 2026 | Yahoo Finance |
Halozyme Therapeutics (HALO) Stock Gets Fair Value Boost After Q3 Analyst Revisions
Halozyme Therapeutics just saw its modeled fair value move from about US$108.78 to roughly US$119.44, signaling an updated price target range in recent research. Analysts link this shift to Q3 2026 results, the latest ENHANZE driven royalty trends, and a mix of optimism and caution around the… |
| 12 Nov 2026 | Yahoo Finance |
Halozyme Therapeutics (HALO) Stock Looks In Line As ENHANZE Approval Lands
Halozyme Therapeutics has delivered strong multi year gains for shareholders, yet the stock has recently pulled back. This raises a clear question about whether its current valuation is supported by the business's earnings power. Over the past 5 years the share price has climbed 176.2%, which puts… |
| 11 Nov 2026 | Yahoo Finance |
Will HALO's Partner Royalties Drive Growth for the Rest of 2026?
Halozyme's royalty revenues surged 45.8% in the first nine months of 2026, prompting higher guidance. |
| 11 Nov 2026 | Yahoo Finance |
Can You Make Money Off Halozyme Stock Now?
For questions about this article or underlying research, email [email protected]. |
| 11 Nov 2026 | Yahoo Finance |
Halozyme Therapeutics' Current Royalty Portfolio Expected to Peak in 2029, Morgan Stanley Says
Halozyme Therapeutics' (HALO) current royalty portfolio is expected to peak in 2029 as scheduled roy… |
| 10 Nov 2026 | Yahoo Finance |
Are Medical Stocks Lagging Halozyme Therapeutics (HALO) This Year?
Here is how Halozyme Therapeutics (HALO) and Adaptive Biotechnologies (ADPT) have performed compared to their sector so far this year. |
| 10 Nov 2026 | Yahoo Finance |
HALO Q3 2026 deep dive: royalty expansion and next-gen platform investments drive outlook update
Biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) beat Wall Street’s revenue expectations in Q3 2026, with sales up 39.2% year on year to $493 million. The company’s full-year revenue guidance of $1.89 billion at the midpoint came in 0.6% above analysts’ estimates. Its… |
| 10 Nov 2026 | Yahoo Finance |
Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why
Halozyme Therapeutics (HALO) could produce exceptional returns because of its solid growth attributes. |
| 06 Nov 2026 | Yahoo Finance |
HALO Q3 Earnings Call Highlights Royalty Growth and Patent Dispute
Halozyme lifts its 2026 outlook after a 44% royalty surge, as ENHANZE expansion, Hypercon trials and a Merck patent dispute draw investors' focus. |
| 06 Nov 2026 | Yahoo Finance |
Halozyme Therapeutics, Inc. Q3 2026 Earnings Call Summary
Moby summary of Halozyme Therapeutics, Inc.'s Q3 2026 earnings call… |
| 06 Nov 2026 | Yahoo Finance |
Halozyme Stock Down Despite Q3 Earnings and Revenue Beat
HALO's Q3 earnings & revenues beat estimates, driven by higher royalties and product sales. The company raises its 2026 outlook, yet shares fall in after-hours. |
| 06 Nov 2026 | Yahoo Finance |
Halozyme Therapeutics (HALO) Following Record Results And Higher Guidance Is The Stock Still Undervalued
Halozyme Therapeutics (HALO) just posted third quarter 2026 results that featured record revenue of US$492.97 million and net income of US$247.05 million, along with higher full year guidance and ongoing Merck litigation. The latest numbers come after a powerful run in Halozyme Therapeutics’… |
| 06 Nov 2026 | Yahoo Finance |
Halozyme Stocks Slip 4.28% Despite 39% Revenue Growth and Modestly Higher Guidance
Royalty revenue climbed 44%, but the 2026 revenue guidance midpoint rose only about $20 million. |
| 06 Nov 2026 | Yahoo Finance |
Halozyme Reaffirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Medicare Drug Price Negotiation Program Final Rule for IPAY 2029
Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today confirmed that the Company expects zero to minimal royalty revenue impact based on its analysis of the final rule for the Medicare Drug Price Negotiation Program ("Program") issued by the U.S. Centers for Medicare &… |
| 06 Nov 2026 | Yahoo Finance |
U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with Halozyme's ENHANZE® Technology for the Treatment of Advanced Head and Neck Cancer
Halozyme Therapeutics, Inc. (Nasdaq: HALO) (Halozyme) today announced that Johnson & Johnson was granted accelerated approval from the U.S. Food and Drug Administration (FDA) for RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj), which is co-formulated with ENHANZE®, as a single agent for the… |
| Show more | ||
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |